131I effective half-life (Teff) for patients with thyroid cancer

被引：26
作者：
Willegaignon, J.
Malvestiti, Luiz F.
Guimaraes, Maria I. C.
Sapienza, Marcelo T.
Endo, Irene S.
Neto, Guilherme C.
Marone, Marilia
Sordi, Gian-Maria A. A.
机构：
[1] IPEN, Radiol Protect Serv, BR-05508000 Sao Paulo, Brazil
[2] Sociedade Hosp Samaritano, Dept Nucl Med, Sao Paulo, Brazil
[3] Univ Sao Paulo, Hosp Clin, Fac Med, Nucl Med Ctr, Sao Paulo, Brazil
来源：
HEALTH PHYSICS | 2006年 / 91卷 / 02期
关键词：
thyroid; cancer; I-131; radiation protection;
D O I：
10.1097/01.HP.0000202232.98823.87
中图分类号：
X [环境科学、安全科学];
学科分类号：
08 ; 0830 ;
摘要：
Nuclear medicine procedures that use I-131 activity represent significant sources of potential absorbed dose to medical staff, volunteers, and the general public. The potential exposures are due principally from exposures to excreted and retained activities in the patients' bodies. In general, exposure rate decreases in a simple exponential manner. The average effective half-life found for all patients in the study reported here is 11.41 +/- 0.02 h; this information may be used in guidelines on the management of patients in thyroid cancer therapy and for general radioprotection practice.
引用
收藏
页码：119 / 122
页数：4
相关论文
共 11 条
  • [1] BENUA RS, 1962, AMER J ROENTGENOL RA, V87, P171
  • [2] Radioactive waste discharge quantities for patients undergoing radioactive iodine therapy for thyroid carcinoma
    Driver, I
    Packer, S
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (10) : 1129 - 1132
  • [3] Harbert J.C., 1996, Nuclear Medicine. Diagnosis and therapy
  • [4] *INT COMM RAD PROT, 2004, ICRP PUBL, V94
  • [5] THE RADIOIODINE-ACCUMULATING FUNCTION OF THE HUMAN THYROID GLAND AS A DIAGNOSTIC TEST IN CLINICAL MEDICINE
    KEATING, FR
    HAINES, SF
    POWER, MH
    WILLIAMS, MMD
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY, 1950, 10 (11) : 1425 - 1464
  • [6] National Council on Radiation Protection and Measurements, 1970, 37 NCRP
  • [7] NICOLAU W, 1977, TEMAS ATUAIS TIREOID
  • [8] Effective half-life of 131I in thyroid cancer patients
    North, DL
    Shearer, DR
    Hennessey, JV
    Donovan, GL
    [J]. HEALTH PHYSICS, 2001, 81 (03): : 325 - 329
  • [9] RADIOTHERAPEUTIC AGENTS - PROPERTIES, DOSIMETRY, AND RADIOBIOLOGIC CONSIDERATIONS
    SAENGER, EL
    KEREIAKES, JG
    SODD, VJ
    DAVID, R
    [J]. SEMINARS IN NUCLEAR MEDICINE, 1979, 9 (02) : 72 - 84
  • [10] U.S. Nuclear Regulatory Commission, 1997, REL PAT ADM RAD MAT
12